GWA
OCUL icon

GGM Wealth Advisors’s Ocular Therapeutix OCUL Stock Holding History

GGM Wealth Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$388K Hold
47,691
– – 0.22% 84
2024
Q4 		$407K Hold
47,691
– – 0.21% 81
2024
Q3 		$415K Buy
47,691
+11,652
+32% +$96K 0.18% 84
2024
Q2 		$247K Buy
+36,039
New +$222K 0.11% 121

Other funds holding OCUL

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GGM Wealth Advisors's OCUL Position: Q1 2025 in Review

GGM Wealth Advisors held its Ocular Therapeutix (OCUL) position steady in Q1 2025 at 47,691 shares worth $388K. The position accounts for 0.22% of the portfolio, ranked #84.

GGM Wealth Advisors first reported a position in OCUL in Q2 2024 and has held it in 4 quarters since. The position peaked at $415K in Q3 2024. 196 funds tracked by Wall St. Rank hold OCUL as of Q1 2025.

  • GGM Wealth Advisors held 47,691 shares of Ocular Therapeutix worth $388K as of Q1 2025.
  • GGM Wealth Advisors left its Ocular Therapeutix share count unchanged in Q1 2025.
  • Ocular Therapeutix made up 0.22% of GGM Wealth Advisors's portfolio in Q1 2025, its #84 holding.
  • GGM Wealth Advisors first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 4 quarters since.
  • GGM Wealth Advisors's Ocular Therapeutix position peaked at $415K in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2025.

Based on GGM Wealth Advisors's 13F filing for Q1 2025, filed 1 May 2025.